Predictive Oncology Inc. (NASDAQ: POAI) Subsidiaries Ink Significant Contract, Announce Sale of Media to Top Medical Centers
POAI subsidiary inks contract with significant pharmaceutical company TumorGenesis announces sale of media to research medical centers in New York City, Boston Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales worldwide by 2027 Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its wholly owned subsidiaries, Soluble Biotech, recently inked another contract with a large pharmaceutical company (https://ibn.fm/OpaJb). POAI also announced that TumorGenesis, one of its wholly owned subsidiaries, has sold media to two top research medical centers (https://ibn.fm/uXorQ). Soluble Biotech’s contract will…